1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 05 OCTOBER 2015

Cancer Drug News 05 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 8 pages

Industry Trend Analysis - Roche's Entry Into Checkpoint Inhibition Market Imminent
Industry Brief - Phase II Xtandi Data Demonstrate Potential Advantages Of Genomic Profiling Assay
Industry Brief - R-Pharm US Acquires Ixempra From BMS
Industry Brief - Janssen's Daratumumab Accepted For CHMP Accelerated Assessment
Industry Trend Analysis - Wave Of Positive Anti-CSC Data Crucial To Rebuilding Confidence
Industry Brief - Data Support Continued Development Of Cyramza In Urothelial Carcinoma
Industry Brief - First Data From The Prostate Cancer Registry Released At ECC 2015
Industry Brief - Tasquinimod Does Not Improve OS In mCRPC
Industry Brief - Roche's anti-PDL1 Achieves Positive Results In Phase II mUC Study
Industry Brief - Blueprint Medicines Receives FDA ODD For HCC Candidate
Industry Brief - Merck/DNAtrix Enter Phase II Immuno-oncology Collaboration
Industry Brief - FDA Grants Avelumab ODD For Merkel Cell Carcinoma
Industry Brief - Opdivo+Yervoy Regimen Gains FDA Approval For BRAF V600 Wild-Type MM
Industry Trend Analysis - Novartis Deal Offers XOMA Recovery Opportunity
Industry Brief - Clovis Achieves US/EU Regulatory Milestones For Rociletinib
Industry Trend Analysis - Companion Diagnostic Not Enough To Secure Avelumab Market Share
Industry Brief - Yondelis Approved In Japan For STS

Table Of Contents

Cancer Drug News 05 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Cervical Cancer Statistics

  • November 2016
    6 pages
  • Cervical Cancer  

    Vaccine  

    HPV Vaccine  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.